Search 

Barrington James are a global staffing and resourcing organisation who specialise in placing niche consultants of all levels in the Biotech and Pharmaceutical industry. We offer both short and long term solutions and can provide ad-hoc consultancy support as required. Our offices in Europe, USA and APAC means that we can provide a truly global solution and experience in a market you may not know.

All of our team are dedicated market specialists with unrivalled candidate networks and will be on hand in Hamburg to discuss any assistance you may need to aid you getting your product to market. We have proven experience in knowing  the difference between working for a big pharma and a new start-up Biotech and will ensure that the people you hire truly understand your business and what you need to succeed.

The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. We are an award-winning trade association representing more than 500 member companies including:  • Start-ups, biotechnology and innovative life science companies 
• Pharmaceutical and technological companies 
• Universities, research centres, tech transfer offices, incubators and accelerators
• A wide range of life science service providers: investors, lawyers, IP consultants and IR agencies Explore opportunities to influence, connect and save with the BIA.

BioPartner is a UK Accredited Trade Organisation that leads the UK Delegation to several partnering conferences each year, and for this event, we will be happy to meet with anybody interested in boosting their international trade or locating in the UK. 

We facilitate international partnering for  trade, investment and collaborations for UK based Life Sciences organisations. As a membership organisation, we support our members and other UK SMEs and startups, and we signpost global interest to UK expertise.

#internationaltrade #discounts #events #partnering #unitedkingdom

The company was founded in 2016 by Dr Mark Kotter from his labs at the University of Cambridge. It has raised over $150m in funding so far, has over 180 employees and is headquartered in Cambridge, UK and San Francisco, US. bit.bio combines the concepts of cellular reprogramming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision cellular reprogramming technology, opti-ox™ - a core component of our Cell Identity Coding Platform. opti-ox is a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through rapid reprogramming of stem cells. ioCells™
Under our ioCells brand we have a wide range of wild type and disease model cells available for research and drug discovery including human iPSC-derived nerve, immune and muscle cells. Our portfolio is expanding at pace and all our cells are powered by opti-ox so are consistent, easy to use and highly defined. Cell therapy
We are currently building a clinical pipeline of cell therapies. Our areas of development are liver, immune and metabolic.